Printer Friendly

Hepatitis A, Italy.

To the Editor: Hepatitis A virus (HAV) infection rates are very low in industrialized countries. A noticeable fall in the prevalence of HAV antibodies (anti-HAV) has been reported in southern European and Mediterranean countries such as Spain (1) and Greece (2), reflecting improvements in hygiene standards in the last decades.

An HAV prevalence of 66.3% in 1981 (3) and 29.4% in 1990 (4) was shown in studies conducted in military recruits from all Italian regions. In both studies, subjects from southern regions had a higher HAV prevalence than those from north-central regions. In 2003, we conducted a study of recruits to show changes in HAV infection prevalence in younger Italian generations.

Military service was compulsory in Italy at that time; all men 18-26 years of age were included. From September to December 2003, 323 recruits 18-26 years of age (mean age 20 years), representing all Italian regions, who had been accepted for Air Force military service were tested for anti-HAV in the recruitment center at Viterbo. This recruitment center, used in the 1990 study, was chosen again because it is located near Rome and adherence to protocol was easier to control.

A standard, precoded questionnaire was designed to collect information in the same sequence as questions asked by military personnel during the examination. The same information was collected as in the previous studies: date of birth, residence, father's years of education, and family size. After informed consent was obtained, blood samples were collected and stored at -30[degrees]C until tested. No person was vaccinated against HAV. Anti-HAV assay was performed by using commercial immunoenzymatic method (Abbot Laboratories, North Chicago, IL, USA). The methods used in the 1981 and 1990 studies have similar sensitivity and specificity between them and in relation to that used in the current study, and are detailed elsewhere (3,4).

The prevalence of anti-HAV declined from 66.3% in 1981 to 5.3% in 2003 (p<0.01, [chi square] test). In 2003, the prevalence was 2.1% in the north-central region and 7.9% in southern regions (Figure). However, southern residents were more likely to have been exposed to HAV than north-central residents (p<0.02, [chi square] test). No statistical difference relative to father's years of education or family size was shown. Basic requirements for Navy (1981 study) and Air Force (1990 and 2003 studies) enrollment were similar. Thus, the 3 studies are comparable and a valid estimation of epidemiologic changes over time.

The anti-HAV prevalence shown in this study (5.3%) indicates that Italy has very low endemicity of HAV infection, at least in the young male population. The decline of HAV infection for >20 years is a consequence of good sanitation and hygienic conditions (vaccination against HAV is rarely performed in Italy) and has generated an increasing proportion of adults who are susceptible to this virus at an age characterized by the likely occurrence of a more severe clinical illness (5). This situation will likely necessitate costly interventions, such as vaccinating risk groups (e.g., military personnel, healthcare workers), to prevent HAV infection. Thus, HAV vaccination has been included in the compulsory vaccination schedule of the Italian military personnel since 1998 (6).

Acknowledgments

We thank A. Fantera, G. Grieco, G. Pascali, and A. Piergiovanni of the Health Service of Viterbo recruitment center for crucial support in developing this project.

Raffaele D'Amelio, * ([dagger]) Alfonso Mele, ([double dagger]) Andrea Mariano, ([double dagger]) Luisa Romano, ([section]) Roberto Biselli, ([paragraph]) Florigio Lista, (#) Alessandro Zanetti, ([section]) and Tommaso Stroffolini ([double dagger]) **

* Direzione Generale della Sanita Militare, Rome, Italy; ([dagger]) Universita degli Studi "La Sapienza" II Facolta di Medicina e Chirurgia, Rome, Italy; ([double dagger]) Istituto Superiore di Sanita, Rome, Italy; ([section]) Istituto di Virologia, Universita degli Studi, Milano, Italy; ([paragraph]) Centro Sperimentale di Volo, Pratica di Mare, Italy; (#) Centro Studi e Ricerche di Sanita e Veterinaria, Rome, Italy; and ** Ospedale S. Giacomo, Rome, Italy

References

(1.) Dal-Re R, Garcia-Corbeira P, Garcia-de-Lornas J. A large percentage of the Spanish population under 30 years of age is not protected against hepatitis A. J Med Virol. 2000;60:363-6.

(2.) Papaevangelou G. Epidemiology of hepatitis A in Mediterranean countries. Vaccine. 1992;10:63-6.

(3.) Pasquini P, Kahn HA, Pileggi D, Pana A, Terzi T, D'Arca T. Prevalence of hepatitis A antibodies in Italy. Int J Epidemiol. 1984;13:83-6.

(4.) Stroffolini T, D'Amelio R, Matricardi PM, Chionne P, Napoli A, Rapicetta M, et al. The changing epidemiology of hepatitis A in Italy. Ital J Gastroenterol. 1993;25: 372-4.

(5.) Siegl G. Hepatitis A virus infection. A review. Schweiz Rundsch Med Prax. 2003;92:1659-73.

(6.) D'Amelio R, Biselli R, Natalicchio S, Lista F, Peragallo MS. Vaccination programmes in the Italian military. Vaccine. 2003;21:3530-3.

Address for correspondence: Raffaele D'Amelio, Universita "La Sapienza" II Facolta di Medicina e Chirurgia, Ospedale S. Andrea Via di Grottarossa 1039 00189, Rome, Italy; fax: 39-06-8034-5427; email: raffaele.damelio@ospedalesantandrea.it
COPYRIGHT 2005 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:LETTERS
Author:Stroffolini, Tommaso
Publication:Emerging Infectious Diseases
Article Type:Letter to the Editor
Date:Jul 1, 2005
Words:818
Previous Article:West Nile virus detection and commercial assays.
Next Article:Stenotrophomonas maltophilia in salad.


Related Articles
Eugene woman's efforts give afflicted hope.
Carteggio degli oratori mantovani alla corte sforzesca (1450-1500). .
John Smigley, devoted Veneta citizen, dies at 83.
Deadline looms for students' shots.
VALEANT BEGINS CLINICAL DEVELOPMENT OF VIRAMIDINE IN JAPAN.
UO women get pair of commitments.
iLife '06 and iWork '06: Apple.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters